The role of tissue factor and factor VIIa in hemostasisNigel Mackman
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, NC 27599 7035, USA
Anesth Analg 108:1447-52. 2009
..However, the mechanism by which recombinant FVIIa restores hemostasis has not been clearly defined. In conclusion, the TF:FVIIa complex is essential for hemostasis and recombinant FVIIa is an effective hemostatic drug...
- Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease
Pichika Chantrathammachart
Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, NC 27599, USA
Blood 120:636-46. 2012
..Furthermore, it appears that TF contributes to these processes without affecting intravascular hemolysis...
- Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin
A Phillip Owens
Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
J Clin Invest 122:558-68. 2012
..Our results suggest that the prothrombotic state associated with hypercholesterolemia is caused by oxLDL-mediated induction of TF expression in monocytes via engagement of a TLR4/TLR6 complex...
- Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer
Jian guo Wang
Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Blood 119:5543-52. 2012
..The results of the present study using a xenograft mouse model suggest that tumor TF activates coagulation, whereas TF on circulating MPs may trigger venous thrombosis...
Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activityJeremiah C Boles
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Thromb Res 129:197-203. 2012
..Malignancy conveys an increased risk for thrombosis and chemotherapy further elevates this risk. The pathophysiological mechanisms underlying this process remain poorly defined...
- Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice
Rafal Pawlinski
Hematology and Oncology Division, Department of Medicine, University of North Carolina at Chapel Hill, NC, USA
Blood 116:806-14. 2010
..Our data demonstrate that in a mouse model of endotoxemia activation of the coagulation cascade is initiated by TF expressed by myeloid cells and an unidentified nonhematopoietic cell type(s)...
- PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI
Raj S Kasthuri
Division of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Blood 119:5285-93. 2012
..Our data suggest that monocyte TF may contribute to the development of thrombosis in patients with HIT...
- Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies
Surya V Seshan
Department of Pathology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Blood 114:1675-83. 2009
..Treatment with pravastatin, which down-regulates glomerular TF synthesis, prevents aPL-induced TMA in this mouse model, thus emphasizing that targeting TF might be a good therapeutic intervention in patients with TMA...
- Tissue factor and thrombosis: The clot starts here
A Phillip Owens
Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, USA
Thromb Haemost 104:432-9. 2010
..Understanding the role of TF in thrombosis may permit the development of new antithrombotic drugs. This review will focus on the role of TF in in vivo models of thrombosis...
- Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays
Raj S Kasthuri
Division of Hematology and Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Semin Thromb Hemost 36:764-71. 2010
..Therefore, there is a need to develop sensitive and specific assays for measuring levels of functional TF and TFPI in whole blood and plasma. These assays could be useful in patient management in many scenarios...
- Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury
Silvio Antoniak
Division of Hematology Oncology, Department of Medicine, UNC McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7035, USA
Arterioscler Thromb Vasc Biol 30:2136-42. 2010
..To investigate the effect of protease-activated receptor (PAR) 2 deficiency on ischemia/reperfusion (I/R) injury-induced infarct size, inflammation, heart remodeling, and cardiac function...
- Microparticles in hemostasis and thrombosis
A Phillip Owens
Division of Hematology Oncology, Department of Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill, North Carolina, USA
Circ Res 108:1284-97. 2011
..This review will summarize our current knowledge of the role of procoagulant MPs in hemostasis and thrombosis...
- New insights into the mechanisms of venous thrombosis
Nigel Mackman
Division of Hematology Oncology, Department of Medicine, UNC McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
J Clin Invest 122:2331-6. 2012
..Subsequent activation of the leukocytes induces expression of the potent procoagulant protein tissue factor that triggers thrombosis. Understanding the mechanisms of venous thrombosis may lead to the development of new treatments...
- Role of tissue factor in cancer
Raj S Kasthuri
Division of Hematology and Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
J Clin Oncol 27:4834-8. 2009
..Nevertheless, additional studies are needed to determine if this strategy can be successfully translated to the treatment of cancer patients...
- Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism
David A Manly
Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7035, USA
Thromb Res 125:511-2. 2010
..7+/-3.8 pg/mL vs 0.6+/-0.4 pg/mL, p<0.05). Further prospective studies are required to determine if levels of MP TF activity may be a useful biomarker to identify patients at increased risk for VTE...
- Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque
A Phillip Owens
Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, 98 Manning Drive Campus Box 7035, Chapel Hill, NC 27599, USA
Thromb Res 129:S30-3. 2012
..This review will summarize the connections between hyperlipidemia and TF expression within atherosclerotic plaques and circulating monocytes, as well as its inhibition by statins...
- Protease-activated receptors and myocardial infarction
Silvio Antoniak
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
IUBMB Life 63:383-9. 2011
..These discrepant results between genetic and pharmacological approaches indicate that further studies are needed to determine the role of different PARs in the injured heart...
- Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner
Jian guo Wang
Division of Hematology and Oncology, Department of Medicine, McAllister Heart Institute, Chapel Hill, NC, USA
Blood 118:2366-74. 2011
..Therefore, monocytic MPs contain IL-1β and may amplify inflammation by enhancing the activation of the endothelium...
- Cellular sources of tissue factor in endotoxemia and sepsis
Rafal Pawlinski
Hematology and Oncology Division, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516, USA
Thromb Res 125:S70-3. 2010
..This review focuses on tissue factor expression by hematopoietic and non-hematopoietic cells and its contribution to the activation of coagulation during endotoxemia and sepsis...
Tissue factor in health and diseaseJulie C Williams
Division of Hematology and Oncology, Department of Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill, North Carolina, USA
Front Biosci (Elite Ed) 4:358-72. 2012
..Pathologic TF expression is found in patients with a number of different diseases. This review will describe the roles of TF in health and disease as well as discuss approaches to reduce pathologic TF expression...
- Effect of PAR-2 Deficiency in Mice on KC Expression after Intratracheal LPS Administration
Julie C Williams
Division of Hematology and Oncology, Department of Medicine, McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7035, USA
J Signal Transduct 2011:415195. 2011
..Infiltration of neutrophils and macrophages into the lung following LPS administration was not affected by an absence of PAR-2. Our results support the notion that PAR-2 plays a role in LPS activation of TLR4 signaling in macrophages...
- Triggers, targets and treatments for thrombosis
Nigel Mackman
Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Nature 451:914-8. 2008
..The pathogenic changes that occur in the blood vessel wall and in the blood itself resulting in thrombosis are not fully understood. Understanding these processes is crucial for developing safer and more effective antithrombotic drugs...
- Tissue factor and its measurement in whole blood, plasma, and microparticles
Nigel S Key
Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Semin Thromb Hemost 36:865-75. 2010
..We comment on some of the crucial preanalytical and analytical variables that influence the results and their interpretation...
- Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation
Ilene C Weitz
Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles 90033, CA, USA
Thromb Res 130:361-8. 2012
....
- Role of tissue factor in atherothrombosis
A Phillip Owens
Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, 98 Manning Drive Campus Box 7035, Chapel Hill, NC 27599, USA
Curr Atheroscler Rep 14:394-401. 2012
..In addition, currently used therapeutics, such as statins and inhibitors of the renin angiotensin system, may have additional benefits by reducing TF expression and subsequent thrombosis...
- Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis
Noppacharn Uaprasert
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Eur J Cancer 46:1790-9. 2010
..These studies may not only yield greater insight into the pathogenesis of disease but may also define novel targets for the prevention and treatment of thromboembolic events in patients with multiple myeloma...
- Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury
Patricia Redecha
Hospital for Special Surgery, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
Blood 110:2423-31. 2007
..The identification of TF as an important mediator of C5a-induced oxidative burst in neutrophils in aPL-induced fetal injury provides a new target for therapy to prevent pregnancy loss in the antiphospholipid syndrome...
- Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial
David A Morrow
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Eur Heart J 26:682-8. 2005
..Sunol-cH36, a chimaeric monoclonal antibody to TF, blocks binding of factor X to the TF:VIIa complex. This report describes the first completed trial of Sunol-cH36 in humans...
- Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1
Udo Bavendiek
Leducq Center for Cardiovascular Research, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Biol Chem 277:25032-9. 2002
....
